ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 12, 2010, Pages 2394-2396

  Sobajima, Jun ^a   Haga, Norihiro ^a   Kumamoto, Kensuke ^a   Ishibashi, Keiichiro ^a   Ishida, Hideyuki ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; Excision repair cross complementing 1 (ERCC1); Thymidylate synthase (TS)

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; ENDOSCOPIC BIOPSY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 84866620496     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Ishida K, Ando N, Yamamoto S, et al: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) J Japan Clinical Oncology Group trial (JCOG9516 ).Jpn J Clin Oncol 34 (10): 615-619, 2004. (Pubitemid 40662717)
2. Yamachika T. Nakanishi H, Inada K. et al: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82(1): 70-77,1998. (Pubitemid 28070481)
3. Kwon HC, Roh MS, Oh SY, et al: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transfererase PI for 5-fluorouracilJoxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18 (3): 504-509. 2007. (Pubitemid 46359630)
4. Therasse P, Arbuck SG, Eisenhauer EA, et al: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3): 205-216, 2000. (Pubitemid 30099779)
5. Kim SH. Kwon HC, Oh SY, et al: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-trans-ferase n for 5-FUJoxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 32(1): 38-43. 2009.
6. Jun HJ, Ahn MJ, Kim HS, et al: ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99 (1): 167-172.2008. (Pubitemid 351920246)
7. Koh Y, Kim TM, Jeon YK, et al: Class HI J?-tubulia but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 20(8): 1414-1419.2009.
8. Joshi MB, Shirota Y, Danenberg KD, et al: High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11(6): 2215-2221,2005.